Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
← catalyst calendarNCT07231419 · readout in 229 d
Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
734estimated
Sites
75
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-21 | actual | When the study began enrolling |
| Primary completion | 2027-04-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-06 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetic Peripheral Neuropathic Pain
Interventions
- Drug: Suzetrigine — also filed as VX-548, SUZ
- Drug: Placebo (matched to SUZ)
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo
measured From Baseline up to Week 12
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed